Mary Jo Rademacher - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Mary Jo Rademacher

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Experimental and Molecular Pathology|May 10, 2024

Fate control engagement augments NK cell responses in LV/hu-IL-12 transduced sarcomaMary Jo Rademacher, Mary L Faber, Kathleen M Bone, et al.

Scientific Reports|April 16, 2021

Sarcoma IL-12 overexpression facilitates NK cell immunomodulationMary Jo Rademacher, Anahi Cruz, Mary Faber, et al.

Frontiers in Immunology|August 30, 2023

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activityMary L Faber, Robyn A A Oldham, Archana Thakur, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Experimental and Molecular Pathology|May 10, 2024

Fate control engagement augments NK cell responses in LV/hu-IL-12 transduced sarcomaMary Jo Rademacher, Mary L Faber, Kathleen M Bone, et al.

Scientific Reports|April 16, 2021

Sarcoma IL-12 overexpression facilitates NK cell immunomodulationMary Jo Rademacher, Anahi Cruz, Mary Faber, et al.

Frontiers in Immunology|August 30, 2023

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activityMary L Faber, Robyn A A Oldham, Archana Thakur, et al.

Pageof 1